Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**(R)-ibuprofen** is the R-enantiomer (also called the distomer) of ibuprofen, a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid. Ibuprofen is usually administered as a racemic (1:1) mixture of its S- and R- enantiomers. While the S-enantiomer ((S)-ibuprofen, also called dexibuprofen) is responsible for the pharmacological (anti-inflammatory, analgesic, antipyretic) effects, the R-enantiomer has little direct therapeutic activity. However, in the body, (R)-ibuprofen can undergo conversion (chiral inversion) to the active (S)-enantiomer via an isomerase enzyme (alpha-methylacyl-CoA racemase). Direct administration of pure (R)-ibuprofen is rare, as most clinical formulations contain the racemic mixture or the pure S-enantiomer for therapeutic effect.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on r-ibuprofen.